Seven numbers in the abstract
Where each one falls
Where it lands on the map
What it changes
Among 10 other studies
the abstract, start to end
… had lower rates of all-cause death (HR: 0.81; 95% CI: 0.71-0.93), CV death (HR: 0.85; 95% CI: 0.71-1.01), and non-CV death (HR: 0.77; 95% CI: 0.62-0.95).
… sudden cardiac death (98 vs 109; HR: 0.89; 95% CI: 0.68-1.17) and undetermined death (77 vs 90; HR: 0.85; 95% CI: 0.63-1.15).
… vs the placebo group (62 vs 87; HR: 0.71; 95% CI: 0.51-0.98).
… 0.04) or died of COVID-19 (43 vs 65; HR: 0.66; 95% CI: 0.44-0.96).
← favours treatmentfavours comparator →
could be chanceAll-cause mortality
HR 0.810.71–0.93
Cardiovascular events
HR 0.890.68–1.17
All-cause mortality
HR 0.850.71–1.01
Cardiovascular events
HR 0.710.51–0.98
Cardiovascular events
HR 0.850.63–1.15
All-cause mortality
HR 0.770.62–0.95
Adverse events & safety
HR 0.660.44–0.96
GLP-1 receptor agonistsCardiovascular eventsAll-cause mortalityAdverse events & safety
GLP-1 receptor agonists × cardiovascular eventshelps?mixed
unlikelylikely
0.500.50 without it
GLP-1 receptor agonists × all-cause mortalityhelps?replicated
unlikelylikely
0.880.86 without it
GLP-1 receptor agonists × adverse events & safetyharms?mixed
unlikelylikely
0.020.02 without it
← favours treatmentfavours comparator →
1 / 5